Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00488514
First received: June 18, 2007
Last updated: May 31, 2012
Last verified: March 2011
Results First Received: August 6, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Migraine Disorders
Intervention: Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
85 mg Sumatriptan/500 mg Naproxen Sodium Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium. A single Combination Tablet was supplied for each migraine attack, not to exceed one tablet in 24 hours.

Participant Flow:   Overall Study
    85 mg Sumatriptan/500 mg Naproxen Sodium  
STARTED     656  
COMPLETED     363  
NOT COMPLETED     293  
Adverse Event                 41  
Lost to Follow-up                 44  
Protocol Violation                 32  
Withdrawal by Subject                 106  
Lack of Efficacy                 28  
Did not meet criteria for treatment                 30  
Postive drug screen                 1  
Withdrawn per medical monitor decision                 2  
Investigator decision                 1  
Participant had too few migraines                 5  
Increase in number of migraines                 2  
Increased use of concomitant medication                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
85 mg Sumatriptan/500 mg Naproxen Sodium Combination Tablet: 85 milligrams (mg) sumatriptan and 500 mg naproxen sodium.

Baseline Measures
    85 mg Sumatriptan/500 mg Naproxen Sodium  
Number of Participants  
[units: participants]
  622  
Age [1]
[units: Years]
Mean ± Standard Deviation
  14.7  ± 1.68  
Gender  
[units: Participants]
 
Female     367  
Male     255  
Race/Ethnicity, Customized  
[units: participants]
 
Caucasian     527  
Africian American     71  
American Indian or Alaskan Native     10  
Asian     4  
African American/African Heritage and Asian     2  
African American/African Heritage and White     3  
American Indian or Alaskan Native and White     5  
[1] Baseline data were collected in the Safety Population, comprised of all participants in the Enrolled Population (all participants entered into the trial and categorized as "started" in the Participant Flow module) who took at least one dose of study drug.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With the Indicated Drug-related Adverse Events   [ Time Frame: Baseline through End of Study (up to Month 12) ]

2.  Secondary:   Number of Participants With Any Adverse Event Categorized by Severity   [ Time Frame: Baseline through End of Study (up to Month 12) ]

3.  Secondary:   Number of Participants With Any Adverse Event Categorized Over Time   [ Time Frame: Baseline through End of Study (up to Month 12) ]

4.  Secondary:   Number of Participants With Any Adverse Event Categorized by Participant Age   [ Time Frame: Baseline through End of Study (up to Month 12) ]

5.  Secondary:   Number of Participants With Any Adverse Event Categorized by Participant Race   [ Time Frame: Baseline through End of Study (up to Month 12) ]

6.  Secondary:   Number of Participants With Any Adverse Event Categorized by Participant Gender   [ Time Frame: Baseline through End of Study (up to Month 12) ]

7.  Secondary:   Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

8.  Secondary:   Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

9.  Secondary:   Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit   [ Time Frame: Baseline through End of Study (up to Month 12) ]

10.  Secondary:   Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit   [ Time Frame: Baseline through End of Study (up to Month 12) ]

11.  Secondary:   Mean Height for All Study Participants at the Indicated Time Points   [ Time Frame: Screening and Months 3, 6, 9, and 12 ]

12.  Secondary:   Mean Weight for All Study Participants at the Indicated Time Points   [ Time Frame: Screening and Months 3, 6, 9, and 12 ]

13.  Secondary:   Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points   [ Time Frame: Screening and Months 3, 6, 9, and 12 ]

14.  Secondary:   Mean Blood Pressure for All Study Participants at the Indicated Time Points   [ Time Frame: Screening and Months 3, 6, 9, and 12 ]

15.  Secondary:   Mean Heart Rate for All Study Participants at the Indicated Time Points   [ Time Frame: Screening and Months 3, 6, 9, and 12 ]

16.  Secondary:   Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator   [ Time Frame: Screening and Final Visit (up to Month 12) ]

17.  Secondary:   Number of Treated Migraine Attacks   [ Time Frame: Baseline through End of Study (up to Month 12) ]

18.  Secondary:   Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

19.  Secondary:   Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

20.  Secondary:   Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

21.  Secondary:   Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month   [ Time Frame: Baseline through End of Study (up to Month 12) ]

22.  Secondary:   Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet   [ Time Frame: Baseline through End of Study (up to Month 12) ]

23.  Secondary:   Number of Migraine Attacks Rated With the Indicated Pain Severity   [ Time Frame: Baseline through End of Study (up to Month 12) ]

24.  Secondary:   Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting   [ Time Frame: Baseline through End of Study (up to Month 12) ]

25.  Secondary:   Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12   [ Time Frame: Baseline and Months 3, 6, 9, and 12 ]

26.  Secondary:   Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionnaire–Revised (PPMQ-R) at the Screening Visit   [ Time Frame: Screening ]

27.  Secondary:   Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionaire–Revised (PPMQ-R) at Month 12   [ Time Frame: End of Study/Month 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


Publications of Results:
McDonald SA, Hershey AD, Pearlman EM, Winner PK, Rothner DA, Linder SL, Richard NE, Derosier FJ. Long-term safety and tolerability of a single, fixed-dose tablet of sumatriptan and naproxen sodium (SumaRT/Nap) in adolescent migraineurs. Headache. 2010; 48.

Publications automatically indexed to this study:

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00488514     History of Changes
Other Study ID Numbers: TXA107977
Study First Received: June 18, 2007
Results First Received: August 6, 2010
Last Updated: May 31, 2012
Health Authority: United States: Food and Drug Administration